FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.
Offering an ultrasound platform that may have the capability to upgrade two-dimensional (2D) ultrasound devices with access to three-dimensional (3D) views of thyroid conditions, the Piur tUS Infinity system has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The Piur tUS Infinity platform enables clinicians to obtain multiplanar reconstructions from a single sweep with a traditional 2D ultrasound device, according to Piur Imaging, the developer of Piur tUS Infinity.
The newly FDA-cleared Piur tUS Infinity platform enables clinicians to obtain 3D multiplanar reconstructions from a single sweep with a traditional 2D ultrasound device, according to Piur Imaging, the developer of Piur tUS Infinity. (Image courtesy of Piur Imaging.)
Providing detailed volumetric assessment of thyroid lobes and nodules with a single scan, Piur Imaging said the Piur tUS Infinity platform facilitates nodule classification with the Thyroid Imaging Reporting and Data System (TI-RADS). The company added that the Piur tUS Infinity platform facilitates standardized reporting for PACS systems, and use of the 3D system may be reimbursed via CPT Category I code 76377.
“This technology offers an enhanced view into thyroid conditions, enabling clinicians to make more informed, precise decisions in patient care,” noted Frederik Bender, the chief executive officer of Piur Imaging.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
